Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar ...
Novartis plans to cut as many as 680 jobs in development, Sanofi's pipeline reprioritization project will result in layoffs.
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of ...
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Not only did it help patients lose weight, but they were also able to keep the weight off for up to 150 days following the last dose of the medicine. Amgen plans on releasing results from phase 2 ...
Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli ...
Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol a ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...